Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Bactericidal Activity of Telacebec in Pulmonary Tuberculosis
NCT03563599Phase 2Completed
- Sponsor
- Qurient Co., Ltd.
- Start
- Jul 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Telacebec in pulmonary tuberculosis (TB) (4 arms), sponsored by Qurient Co., Ltd. Primary endpoint: Early Bactericidal Activity. Started Jul 2018; status: completed.
02
Drugs
Telacebec
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT03563599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563599.